The renal protective effects of angiotensin II receptor blockers in type 2 diabetes mellitus
The renal protective effects of angiotensin II receptor blockers in type 2 diabetes mellitus
复制标题
DOI：
10.1345/aph.1e182
复制
发表时间：
2004-10-01
影响因子：
2.9
通讯作者：
White, CM
中科院分区：
文献类型：
--
作者：
Coyle, JD;Gardner, SF;White, CM
目的：综述血管紧张素II受体阻滞剂（ARB）对2型糖尿病患者肾脏的保护作用。（1966- 2004年3月）完成，使用厄贝沙坦、坎地沙坦、氯沙坦、缬沙坦、依普罗沙坦、奥美沙坦、替米沙坦、肾保护、肾病、蛋白尿和2型糖尿病作为关键词。对所有识别出的英文文献进行了审查。已识别来源的参考文献用于识别其他文章。文章代表的主题，我们的reviewed.DATA综合：ARBs有广泛的数据显示其肾脏保护的好处，在高血压2型糖尿病患者微量白蛋白尿或蛋白尿。其益处超过单独降低血压的益处，并且还扩展到血压正常的糖尿病患者。最大限度地增加额外的治疗或另一种肾脏保护剂（血管紧张素转换酶[ACE]抑制剂或非二氢吡啶类钙通道阻滞剂）之前的ARB剂量可能是上级添加另一类抗高血压，即使类似的血压可以实现.CONCLUSIONS：ARB是一个重要的治疗高血压2型糖尿病患者，可以受益血压正常的糖尿病患者以及。ARB剂量优化或添加第二种肾保护剂（ACE抑制剂或非二氢吡啶类钙通道阻滞剂）可能对最佳肾保护作用很重要，尽管在该领域显然需要进一步研究。
OBJECTIVE: To review the renal protective effects of angiotensin II receptor blockers (ARBs) in patients with type 2 diabetes mellitus.DATA SOURCES: A MEDLINE search (1966-March 2004) was completed using irbesartan, candesartan, losartan, valsartan, eprosartan, olmesartan, telmisartan, renal protection, nephropathy, albuminuria, and type 2 diabetes mellitus as key words.STUDY SELECTION AND DATA EXTRACTION: All identified English-language articles were reviewed. References of the identified sources were used to identify additional articles. Articles representative of the subject matter of our review were included.DATA SYNTHESIS: ARBs have extensive data showing their renal protective benefits in hypertensive type 2 diabetic patients with microalbuminuria or proteinuria. The benefits are over and above that of blood pressure reduction alone and extend to normotensive diabetic patients as well. Maximizing the ARB dose before adding additional therapies or another renal-protecting agent (angiotensin-converting enzyme [ACE] inhibitor or non-dihydropyridine calcium-channel blocker) may be superior to adding another class of antihypertensive, even if similar blood pressures can be achieved.CONCLUSIONS: ARBs are an important therapy for hypertensive type 2 diabetic patients and can benefit normotensive diabetic patients as well. ARB dosage optimization or the addition of a second renoprotective agent (ACE inhibitor or non-dihydropyridine calcium-channel blocker) may be important for optimal renoprotection, although further research is clearly needed in this area.